Top

Social Psychiatry and Psychiatric Epidemiology

Published in:

01-06-2009 | ORIGINAL PAPER

Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK

A systematic review

Authors: Giuseppe Carrà, Sonia Johnson

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 6/2009

Abstract

Background

Comorbid substance misuse in psychosis is associated with significant clinical, social and legal problems. An epidemiologically informed approach to planning service delivery requires an understanding of which clinical populations are at particularly high risk for such ‘dual diagnosis’. Evidence has now been accumulating in the UK since the early 1990s, and allows a relatively comprehensive comparison of rates between service settings, geographical areas and social contexts in terms of ethnic background.

Methods

A literature search was carried out with the aim of investigating: (a) comorbid alcohol and drug misuse rates in people with established psychosis in different mental health and addiction settings in the UK, (b) variations in such rates between different population groups.

Results

There are wide variations in reported drug and alcohol misuse rates in psychosis. Most recent UK studies report rates between 20 and 37% in mental health settings, while figures in addiction settings are less clear (6–15%). Rates are generally not as high as in US studies, but appear to be especially high in inpatient and crisis team settings (38–50%) and forensic settings. In terms of geography, rates appear highest in inner city areas. Some ethnic groups are over-represented among clinical populations of people with dual diagnosis.

Conclusions

Rates of substance misuse in psychosis are likely to be influenced by service setting, population composition and geography. Acute and forensic settings are especially appropriate for the development of targeted interventions.

Available only for authorised users

Adams CE, Coutinho ESF, Davis J, Duggan L, Leucht S, Li C, Tharyan P (2008) Cochrane Schizophrenia Group. Schizophr Bull 34:259–265PubMed

Afuwape SA, Johnson S, Craig T, Miles H, Leese M, Thornicroft G (2006) Ethnic differences among a community cohort of individuals with dual diagnosis in South London. Journal of Mental Health 15:551–567

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn, revised edn. American Psychiatric Association, Washington, DC

Barnaby B, Drummond C, McCloud A, Burns T, Omu N (2003) Substance misuse in psychiatric inpatients: comparison of a screening questionnaire survey with case notes. BMJ 327:783–784PubMed

Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM (2006) Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 188:237–242PubMed

Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, Pernet DE, Kirkbride JB, Murray GK, Bullmore ET, Jones PB (2007) Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190:515–520PubMed

Bernadt MW, Mumford J, Murray RM (1984) Can accurate drinking histories be obtained from psychiatric patients by a nurse conducting screening interviews? Br J Addict 79:201–206

Bernadt MW, Murray RM (1986) Psychiatric disorder, drinking and alcoholism: what are the links? Br J Psychiatry 148:393–400PubMed

Blane D, Power C, Bartley M (1996) Illness behaviour and the measurement of class differentials in morbidity. J R Stat Soc Ser A Stat Soc 159:77–92

10.

Brady K, Casto S, Lydiard RB, Malcolm R, Arana G (1991) Substance abuse in an inpatient psychiatric sample. Am J Drug Alcohol Abuse 17:389–397PubMed

11.

Brown S (1998) Substance misuse in a chronic psychosis population. Psychiatr Bull R Coll Psychiatr 22:595–598

12.

Burns T, Kendrick T (1997) The primary care of patients with schizophrenia: a search for good practice. Br J Gen Pract 47:515–520PubMed

13.

Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, Harrison G (1999) Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 174:150–153PubMed

14.

Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G (2008) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 1:Art. No.:CD001088

15.

Clifford P (1993) FACE profile. Research Unit, Royal College of Psychiatrists, London

16.

Commander M, Sashidharan S, Rana T, Ratnayake T (2005) North Birmingham assertive outreach evaluation. Patient characteristics and clinical outcomes. Soc Psychiatry Psychiatr Epidemiol 40:988–993PubMed

17.

Corbett M, Duggan C, Larkin E (1998) Substance misuse and violence: a comparison of special hospital inpatients diagnosed with either schizophrenia or personality disorder. Crim Behav Ment Health 8:311–321

18.

Crawford V, Crome IB, Clancy C (2003) Co-existing problems of mental health and substance misuse (dual diagnosis): a literature review. Drugs 10(Suppl 1):1–74

19.

Department of Health (1999) National Service Framework for Mental Health. Modern Standards and Service Models for Mental Health. Department of Health, London

20.

Department of Health (2002) Mental Health Policy implementation guide: dual diagnosis good practice guide. Department of Health, London

21.

Derogatis LR, Melisaratos N (1983) The brief symptom inventory: an introductory report. Psychol Med 13:595–605PubMed

22.

Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148:224–230PubMed

23.

Drake RE, Alterman AI, Rosenberg SR (1993) Detection of substance use disorders in severely mentally ill patients. Community Ment Health J 29:175–192PubMed

24.

Drake RE, Mueser KT, McHugo GJ (1996) Clinician rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS) and Substance Abuse Treatment Scale (SATS). In: Sederer L, Dickey B (eds) Outcomes assessment in clinical practice. Williams and Wilkins, Baltimore

25.

Duke PJ, Pantelis C, Barnes TR (1994) South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 164:630–636PubMed

26.

Duke PJ, Pantelis C, McPhillips MA, Barnes TR (2001) Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. Br J Psychiatry 179:509–513PubMed

27.

European Monitoring Centre for Drugs and Drug Addiction-EMCDDA (2004) Comorbidity—drug use and mental disorders. Drugs Focus 14:1–4

28.

Fakhoury WKH, Priebe S, Study Group PLAO (2006) An unholy alliance: substance abuse and social exclusion among assertive outreach patients. Acta Psychiatr Scand 114:124–131PubMed

29.

Farrell M, Boys A, Bebbington P, Brugha T, Coid J, Jenkins R, Lewis G, Meltzer H, Marsden J, Singleton N, Taylor C (2002) Psychosis and drug dependence: results from a national survey of prisoners. Br J Psychiatry 181:393–398PubMed

30.

Farrell M, Howes S, Taylor C, Lewis G, Jenkins R, Bebbington P, Jarvis M, Brugha T, Gill B, Meltzer H (2003) Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Int Rev Psychiatry 15:43–49PubMed

31.

Fearon P, Kirkbride JB, Morgan C, Dazzan P, Morgan K, Lloyd T, Hutchinson G, Tarrant J, Fung WLA, Holloway J, Mallett R, Harrison G, Leff J, Jones PB, Murray RM (2006) Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol Med 36:1541–1550PubMed

32.

Fleming MF, Barry KL (1991) A three-sample test of an alcohol screening questionnaire. Alcohol Alcohol 26:81–91PubMed

33.

Fowler IL, Carr VJ, Carter NT, Lewin TJ (1998) Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 24:443–455PubMed

34.

Frisher M, Collins J, Millson D, Crome I, Croft P (2004) Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales. J Epidemiol Community Health 58:1036–1041PubMed

35.

Frisher M, Hickman M, Kraus L, Mariani F, Wiessing L (2001) A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction 96:1465–1476

36.

Furr-Holden CDM, Anthony JC (2003) Epidemiologic differences in drug dependence: a US–UK cross-national comparison. Soc Psychiatry Psychiatr Epidemiol 38:165–172PubMed

37.

Gaite L, Vazquez-Barquero JL, Borra C, Ballesteros J, Schene A, Welcher B, Thornicroft G, Becker T, Ruggeri M, Herran A, EPSILON Study Group. (2002) The Epsilon Study Group. Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand 105:283–292PubMed

38.

Ghodse H (2002) Drugs and addictive behaviour. Cambridge University Press, Cambridge

39.

Gossop M, Drake S, Griffiths P, Hando J, Powis B, Hall W, Strang J (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607–614PubMed

40.

Graham HL, Maslin J, Copello A, Birchwood M, Mueser K, McGovern D, Georgiou G (2001) Drug and alcohol problems amongst individuals with severe mental health problems in an inner city area of the UK. Soc Psychiatry Psychiatr Epidemiol 36:448–455PubMed

41.

Grech A, Takei N, Murray RM (1998) Comparison of cannabis use in psychotic patients and controls in London and Malta. Schizophr Res 29:22

42.

Grech A, Takei N, Murray RM (1998) Psychosis and cannabis use. Schizophr Res 29:21

43.

Haddock G, Lewis S, Bentall R, Dunn G, Drake R, Tarrier N (2006) Influence of age on outcome of psychological treatments in first-episode psychosis. Br J Psychiatry 188:250–254PubMed

44.

Havassy BE, Arns PG (1998) Relationship of cocaine and other substance dependence to well-being of high-risk psychiatric patients. Psychiatr Serv 49:935–940PubMed

45.

Hilton ME, Clark WB (1991) Measuring drinking problems in the 1984 National Alcohol Survey. In: Clark WB, Hilton ME (eds) Alcohol in America. State University of New York, Albany

46.

Hunt GE, Bergen J, Bashir M (2002) Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 54:253–264PubMed

47.

Iley K, Nazroo J (2001) Ethnic inequalities in mental health: a critical examination of the evidence. In: Culley L, Dyson S (eds) Sociology, ethnicity and nursing practice. Palgrave, Basingstoke, pp 67–89

48.

Isaac M, Isaac M, Holloway F (2005) Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 20:207–210PubMed

49.

Isherwood S, Brooke D (2001) Prevalence and severity of substance misuse among referrals to a local forensic service. Journal of Forensic Psychiatry 12:446–454

50.

Jenkins R, Bebbington P, Brugha T, Farrell M, Gill B, Lewis G, Meltzer H, Petticrew M (1997) The National Psychiatric Morbidity Surveys of Great Britain—strategy and methods. Psychol Med 27:765–774PubMed

51.

Johnson S (1997) Dual diagnosis of severe mental illness and substance misuse: a case for specialist services? Br J Psychiatry 171:205–208PubMed

52.

Johnson S, Zinkler M, Priebe S (2001) Mental health service provision in England. Acta Psychiatr Scand Suppl 410:47–55PubMed

53.

Johnson S, Nolan F, Hoult J, White IR, Bebbington P, Sandor A, McKenzie N, Patel SN, Pilling S (2005) Outcomes of crises before and after introduction of a crisis resolution team. Br J Psychiatry 187:68–75PubMed

54.

Johnson S, Nolan F, Pilling S, Sandor A, Hoult J, McKenzie N, White IR, Thompson M, Bebbington P (2005) Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study. BMJ 331:599–602PubMed

55.

Johnson S, Thornicroft G, Afuwape S, Leese M, White IR, Hughes E, Wanigaratne S, Miles H, Craig T (2007) Effects of training community staff in interventions for substance misuse in dual diagnosis patients with psychosis (COMO study): cluster randomised trial. Br J Psychiatry 191:451–452PubMed

56.

Kavanagh DJ, Waghorn G, Jenner L, Chant DC, Carr V, Evans M, Herrman H, Jablensky A, McGrath JJ (2004) Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res 66:115–124PubMed

57.

Kendler KS, Gallagher TJ, Abelson JM, Kessler RC (1996) Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. Arch Gen Psychiatry 53:1022–1031PubMed

58.

Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ (1996) The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 66:17–31PubMed

59.

Killaspy H, Bebbington P, Blizard R, Johnson S, Nolan F, Pilling S, King M (2006) The REACT study: randomised evaluation of assertive community treatment in north London. BMJ 332:815–820PubMed

60.

Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Murray RM, Jones PB (2007) Neighbourhood variation in the incidence of psychotic disorders in Southeast London. Soc Psychiatry Psychiatr Epidemiol 42(6):438–445PubMed

61.

Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, Siddle R, Drake R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Faragher B, Dunn G (2002) Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry 181(Suppl. 43):s91–s97

62.

Ley A, Jeffery D, Ruiz J, Mc Laren S, Gillespie C (2002) Underdetection of comorbid drug use at acute psychiatric admission. Psychiatr Bull R Coll Psychiatr 26:248–251

63.

Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K (2004) Drug and alcohol use among patients with schizophrenia and related psychoses: Levels and consequences. Schizophr Res 67:157–166PubMed

64.

Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M (2000) Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry 176:285–289PubMed

65.

McCreadie RG, Scottish Comorbidity Study Group (2002) Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 181:321–325PubMed

66.

McCrone P, Menezes PR, Johnson S, Scott H, Thornicroft G, Marshall J, Bebbington P, Kuipers E (2000) Service use and costs of people with dual diagnosis in South London. Acta Psychiatr Scand 101:464–472PubMed

67.

McGuffin P, Farmer AE, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry 48:764–770PubMed

68.

Menezes PR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P, Kuipers E (1996) Drug and alcohol problems among individuals with severe mental illness in south London. Br J Psychiatry 168:612–619PubMed

69.

Mericle AA, Havassy BE (2008) Characteristics of recent violence among entrants to acute mental health and substance abuse services. Soc Psychiatry Psychiatr Epidemiol 43:392–402PubMed

70.

Miles H, Johnson S, Amponsah-Afuwape S, Finch E, Leese M, Thornicroft G (2003) Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv 54:554–561PubMed

71.

Mowbray CT, Ribisl KM, Solomon M, Luke DA, Kewson TP (1997) Characteristics of dual diagnosis patients admitted to an urban, public psychiatric hospital: an examination of individual, social, and community domains. Am J Drug Alcohol Abuse 23:309–326PubMed

72.

Mueser KT, Bond GR, Drake RE, Resnick SG (1998) Models of community care for severe mental illness: a review of research on case management. Schizophr Bull 24:37–74PubMed

73.

Mueser KT, Essock SM, Drake RE, Wolfe RS, Frisman L (2001) Rural and urban differences in patients with a dual diagnosis. Schizophr Res 48:93–107PubMed

74.

Mueser KT, Yarnold PR, Bellack AS (1992) Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand 85:48–55PubMed

75.

Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Morrison RL, Yadalam KG (1990) Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 16:31–56PubMed

76.

Nazareth I, King M, Haines A, Rangel L, Myers S (1993) Accuracy of diagnosis of psychosis on general practice computer system. BMJ 307:32–34PubMedCrossRef

77.

Office for National Statistics (1991) Census, April 1991. ONS, London

78.

Office for National Statistics (2001) Census, April 2001. ONS, London

79.

Office of the Deputy Prime Minister (2002) Urban and rural area definitions: a user guide. ODPM, London

80.

Phillips P, Johnson S (2003) Drug and alcohol misuse among inpatients with psychotic illnesses in three inner-London psychiatric units. Psychiatr Bull R Coll Psychiatr 27:217–220

81.

Priebe S, Fakhoury W, Watts J, Bebbington P, Burns T, Johnson S, Muijen M, Ryrie I, White I, Wright C (2003) Assertive outreach teams in London: patient characteristics and outcomes. Pan-London Assertive Outreach Study, part 3. Br J Psychiatry 183:148–154PubMed

82.

RachBeisel J, Scott J, Dixon L (1999) Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr Serv 50:1427–1434PubMed

83.

Regier DA, Farmer ME, Rae DS (1990) Co-morbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) study. JAMA 264:2511–2518PubMed

84.

Robins LN, Orvaschel H, Antony J, Blazer D, Burman A, Burke J (1985) The diagnostic interview schedule. In: Eaton WW, Kessler LG (eds) Epidemiologic methods in psychiatry: the epidemiological catchment area program. Academic Press, Orlando, pp 143–171

85.

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addiction 88:791–804PubMed

86.

Schofield N, Quinn J, Haddock G, Barrowclough C (2001) Schizophrenia and substance misuse problems: a comparison between patients with and without significant carer contact. Soc Psychiatry Psychiatr Epidemiol 36:523–528PubMed

87.

Schomerus G, Heider D, Angermeyer MC, Bebbington PE, Azorin JM, Brugha T, Toumi M, European Schizophrenia Cohort (2007) Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC). Soc Psychiatry Psychiatr Epidemiol 42:617–622PubMed

88.

Scott H, Johnson S, Menezes P, Thornicroft G, Marshall J, Bindman J, Bebbington P, Kuipers E (1998) Substance misuse and risk of aggression and offending among the severely mentally ill. Br J Psychiatry 172:345–350PubMed

89.

Singleton N, Bumpstead R, O’Brien M, Lee A, Meltzer H (2001) Psychiatric morbidity among adults living in private households, 2000. The Stationery Office, London

90.

Skinner HA (1982) The drug misuse test. Addict Behav 7:363–371PubMed

91.

Smith SM, Stinson FS, Dawson DA, Goldstein R, Huang B, Grant BF (2006) Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 36:987–998PubMed

92.

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller del D, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA (2006) Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 194:164–172PubMed

93.

Taylor PJ, Leese M, Williams D, Butwell M, Daly R, Larkin E (1998) Mental disorder and violence. Br J Psychiatry 172:218–226PubMed

94.

Urbanoski KA, Cairney J, Adlaf E, Rush B (2007) Substance abuse and quality of life among severely mentally ill consumers: a longitudinal modelling analysis. Soc Psychiatry Psychiatr Epidemiol 42:810–818PubMed

95.

Van Os J, Castle DJ, Takei N, Der G, Murray RM (1996) Psychotic illness in ethnic minorities: clarification from the 1991 Census. Psychol Med 26:203–208

96.

Virgo N, Bennett G, Higgins D, Bennett L, Thomas P (2001) The prevalence and characteristics of co-occurring serious mental illness (SMI) and substance abuse or dependence in the patients of Adult Mental Health and Addictions Services in eastern Dorset. J Mental Health 10:175–188

97.

Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC (2005) Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:629–640PubMed

98.

Weaver T, Hickman M, Rutter D, Ward J, Stimson G, Renton A (2001) The prevalence and management of co-morbid substance misuse and mental illness: results of a screening survey in substance misuse and mental health treatment populations. Drug Alcohol Rev 20:407–416

99.

Weaver T, Madden P, Charles V, Stimson G, Renton A, Tyrer P, Barnes T, Bench C, Middleton H, Wright N, Paterson S, Shanahan W, Seivewright N, Ford C, COSMIC Collaborative study team (2003) Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry 183:304–313PubMed

100.

Weaver T, Rutter D, Madden P, Ward J, Stimson G, Renton A (2001) Results of a screening survey for co-morbid substance misuse amongst patients in treatment for psychotic disorders: prevalence and service needs in an inner London borough. Soc Psychiatry Psychiatr Epidemiol 36:399–406PubMed

101.

Weaver T, Stimson G, Tyrer P, Barnes T, Renton A (2004) What are the implications for clinical management and service development of prevalent comorbidity in UK mental health and substance misuse treatment populations? Drugs: education, prevention. and policy 11:329–348

102.

Wheatley M (1998) The prevalence and relevance of substance misuse in detained schizophrenic patients. J Forensic Psych 9:114–129

103.

Wheatley M (1998) The assessment of substance misuse in the mentally ill detained patient. J Subst Misuse 3:67–72CrossRef

104.

World Health Organization (1973) The International Pilot study of schizophrenia. WHO, Geneva

105.

World Health Organization (1992) SCAN: Schedules for Clinical Assessment in Neuropsychiatry. WHO, Geneva

106.

World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. WHO, Geneva

107.

Wright S, Gournay K, Glorney E, Thornicroft G (2000) Dual diagnosis in the suburbs: prevalence, need, and in-patient service use. Soc Psychiatry Psychiatr Epidemiol 35:297–304PubMed

108.

Young A (2006) Dual diagnosis and forensic care. Are the needs of service users being met? J Psychiatr Ment Health Nurs 13:117–124PubMed

Title: Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK
A systematic review
Authors: Giuseppe Carrà
Sonia Johnson
Publication date: 01-06-2009
Publisher: Steinkopff-Verlag
Published in: Social Psychiatry and Psychiatric Epidemiology / Issue 6/2009
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI: https://doi.org/10.1007/s00127-008-0458-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK

A systematic review

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

“How to spot a psychopath”

Are people with dental fear under-represented in oral epidemiological surveys?

Attitudes and beliefs of patients of first episode depression towards antidepressants and their adherence to treatment

U.S. military mental health care utilization and attrition prior to the wars in Iraq and Afghanistan

The Social Aptitudes Scale: an initial validation

Experiences of victimisation and depression are associated with community functioning among men with schizophrenia